Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Issue Guidances on eConsent, Drug Delivery for Virtual Clinical Trials: Official
May 25, 2022
- Japan Regulators Warn of Monkeypox Cases
May 25, 2022
- MHLW Clarifies LVEF-Related Labeling Rule for Heart Failure Drugs: Q&A
May 24, 2022
- G7 Health Ministers Unite for Boosting Measures for Future Pandemics, AMR
May 24, 2022
- 2 mg Pen of Supply-Crippled Ozempic, 3rd Avastin Biosimilar Get Japan Listing
May 24, 2022
- Japanese Regulators to Accept Online NDA Submissions from July
May 23, 2022
- Japan’s Emergency Approval System Comes into Force, Nod Based on Presumed Efficacy
May 23, 2022
- 12 New Probable Cases of Mysterious Pediatric Hepatitis Detected in Japan
May 23, 2022
- PMDA Reviewing New Safety Risks for Opdivo, Keytruda and More
May 23, 2022
- MOF Budget Examiner Presses for “Full” Annual Re-Pricing, Stepwise Cut in 2% Buffer Zone If No Reasonable Basis Given
May 20, 2022
- Sanofi’s CAD Therapy Sutimlimab Up for PAFSC Review on June 2
May 20, 2022
- Orphan Tag for Pfizer’s Gene Therapy Up for Panel Review on June 1
May 20, 2022
- Investigation of COVID-19 Jab Disposals Not on the Table at This Time: Health Minister
May 20, 2022
- LDP Pharma Study Group to Push Price Maintenance for Patented Meds, Rethink of “Off-Year” Re-Pricing towards Honebuto
May 20, 2022
- LDP Social Security Execs Leery of Macroeconomic Indexing
May 20, 2022
- Chuikyo OKs Listing of 14 Drugs on May 25, Biggest Peak Sales Forecast for Vabysmo
May 19, 2022
- Japan Govt Promulgates Economic Security Law
May 19, 2022
- Cabometyx Likely to Escape CEA Scheme Unscathed with No Price Cut
May 19, 2022
- 4 Drugs Face Zero Premium Rule for Low Cost Disclosures: May Price Listing
May 19, 2022
- Impact of Annual Price Revisions on Pharma Industry Hard to Gauge Comprehensively: Govt
May 19, 2022
ページ
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…